The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
Mark M PomerantzSandor SpisákLi JiaAngel M CroninIstvan CsabaiElisa LedetA Oliver SartorIrene RainvilleEdward P O'ConnorZachary T HerbertZoltan SzállásiWilliam K OhPhilip W KantoffJudy E GarberDeborah SchragAdam S KibelMatthew L FreedmanPublished in: Cancer (2017)
BRCA2-associated, castration-resistant prostate cancer is associated with a higher likelihood of response to carboplatin-based chemotherapy than non-BRCA2-associated prostate cancer. Cancer 2017;123:3532-9. © 2017 American Cancer Society.
Keyphrases
- prostate cancer
- papillary thyroid
- radical prostatectomy
- squamous cell
- squamous cell carcinoma
- locally advanced
- small cell lung cancer
- lymph node metastasis
- breast cancer risk
- randomized controlled trial
- oxidative stress
- dna methylation
- open label
- rectal cancer
- study protocol
- chemotherapy induced
- phase iii
- double blind
- placebo controlled